Blog

Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD

blog.png
iStock_000015336775Medium.jpg

Chronic lymphocytic leukemia (CLL) is a cancer type mainly seen in elderly people, with the average age of diagnosis being 72 years old. However, elderly patients have been underrepresented in CLL clinical trials, and the current gold standard treatment of chemoimmunotherapy is only viable for physically fit people under 65, which rules out the majority of CLL patients. With a high unmet need for improved therapies in CLL, Crown Bioscience reviews the emerging treatment options and whether they offer new hope for older patients.

Read more
iStock_000020334121Medium.jpg

Lung cancer is the biggest cancer killer worldwide, with historically low survival rates and a high number of cases caused by smoking. With targeted therapies now greatly improving treatment options, research is needed to uncover all of the mechanisms and oncogenes which are driving lung cancer forward. Newly published research has identified novel mutations that switch on major oncogenic pathways in lung cancer potentially putting scientists on the right path to new treatments and improved survival for this deadly disease.

Read more
iStock_000004719007Medium.jpg

Radiotherapy is a common treatment for many cancer types, and in recent years has become extremely effective using image guided techniques. However, preclinical irradiation models had fallen behind, with a lack of methods that were comparable to clinical treatments. The game changing small animal radiation research platform (SARRP) from Xstrahl has been turning this around, using Image Guided Micro-Irradiation™ (IGMI) to evaluate preclinical regimens in a clinically relevant way.

Read more
idea-neede-reszied-2.jpg

Type 2 diabetes cannot be cured and is managed by a regimen of exercise, diet, and drugs. As the currently available treatments have a raft of side effects, including weight gain and blood sugar dropping to dangerously low levels, new therapies are needed to control the disease with fewer complications. Some impressive preclinical data were published last month which meet these demands – an FGF1 injection that quickly and effectively lowers blood sugar in diabetic mice with seemingly none of the side effects seen from other antidiabetic agents. Could this be the knockout jab that type 2 diabetes therapies have been looking for?

Read more